INTEGRA Biosciences and Parse Biosciences have partnered to automate single cell RNA sequencing (scRNA-seq) on the ASSIST PLUS pipetting robotic. This new protocol combines Parse Biosciences’ Evercode™ combinatorial barcoding know-how with INTEGRA’s liquid dealing with experience, and is already serving to labs in academia and trade to streamline and standardize their sequencing workflows for sooner throughput and extra reproducible outcomes.
scRNA-seq is an important instrument for increasing information and creating new therapies within the fields of developmental biology, neurology, diabetes, heart problems and most cancers. Parse Biosciences, primarily based in Seattle, Washington, makes a speciality of creating groundbreaking instruments for scRNA-seq at scale. Its proprietary Evercode know-how permits one million cells or nuclei to be ready and sequenced in parallel utilizing a novel labeling technique, with out the necessity for particular person cell isolation.
Parse Biosciences reached out to INTEGRA to co-develop an automatic scRNA-seq answer that might take away a number of the obstacles hindering extra fast progress within the discipline, akin to time-consuming handbook workflows and the prohibitive price of specialised instrumentation generally utilized in different single cell sequencing workflows. Automating Evercode know-how on the ASSIST PLUS pipetting robotic, outfitted with the D-ONE single channel pipetting module and an 8 channel VIAFLO light-weight digital pipette offers an easy-to-use and cost-effective sequencing workflow with 75 % much less hands-on time and 85 % fewer handbook pipetting steps for employees.
This profitable collaboration with INTEGRA has made automation and scRNA-seq way more accessible to labs of all sizes and budgets. Automating the preliminary part of our Evercode protocol on the ASSIST PLUS has sped up our prospects’ workflows and has decreased the probability of human errors, making it a lot simpler for researchers to persistently acquire prime quality scRNA-seq knowledge. We’ve got already developed further workflows on the ASSIST PLUS which are suitable with sections of Evercode TCR and Evercode BCR for T-cell and B-cell receptor profiling, respectively, and we anticipate the automation of the rest of our scRNA-seq protocol on the pipetting platform within the close to future.”
Dr Charlie Roco, Co-founder and CTO, Parse Biosciences